Comparative Pharmacology
Head-to-head clinical analysis: COXANTO versus DIFLUNISAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COXANTO versus DIFLUNISAL.
COXANTO vs DIFLUNISAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of soluble epoxide hydrolase (sEH), increasing levels of epoxyeicosatrienoic acids (EETs), which have vasodilatory, anti-inflammatory, and antifibrotic effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
1 g intravenous every 6 hours.
500 mg to 1000 mg orally initially, then 250 mg to 500 mg every 8 to 12 hours. Maximum daily dose: 1500 mg.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours (prolonged to 24-30 hours in moderate-to-severe renal impairment, requiring dose adjustment)
Clinical Note
moderateDiflunisal + Gatifloxacin
"Diflunisal may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateDiflunisal + Rosoxacin
"Diflunisal may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateDiflunisal + Levofloxacin
"Diflunisal may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateDiflunisal + Trovafloxacin
"Diflunisal may increase the neuroexcitatory activities of Trovafloxacin."
8-12 hours (prolonged in renal impairment; clinical context: permits twice-daily dosing)
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Renal (90% as glucuronide conjugates, <5% unchanged); biliary/fecal (<10%)
Category C
Category C
NSAID
NSAID